Last reviewed · How we verify
Albumin-bound docetaxel — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Albumin-bound docetaxel (Albumin-bound docetaxel) — CSPC ZhongQi Pharmaceutical Technology Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Albumin-bound docetaxel TARGET | Albumin-bound docetaxel | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Albumin-bound docetaxel CI watch — RSS
- Albumin-bound docetaxel CI watch — Atom
- Albumin-bound docetaxel CI watch — JSON
- Albumin-bound docetaxel alone — RSS
Cite this brief
Drug Landscape (2026). Albumin-bound docetaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/albumin-bound-docetaxel. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab